[go: up one dir, main page]

WO1994022429A1 - Procede de traitement d'une tumeur solide - Google Patents

Procede de traitement d'une tumeur solide Download PDF

Info

Publication number
WO1994022429A1
WO1994022429A1 PCT/US1994/003457 US9403457W WO9422429A1 WO 1994022429 A1 WO1994022429 A1 WO 1994022429A1 US 9403457 W US9403457 W US 9403457W WO 9422429 A1 WO9422429 A1 WO 9422429A1
Authority
WO
WIPO (PCT)
Prior art keywords
liposomes
tumor
liposome
antibody
peg
Prior art date
Application number
PCT/US1994/003457
Other languages
English (en)
Inventor
Theresa M. Allen
Francis J. Martin
Martin C. Woodle
Samuel Zalipsky
Original Assignee
Liposome Technology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Technology, Inc. filed Critical Liposome Technology, Inc.
Priority to AU65272/94A priority Critical patent/AU6527294A/en
Publication of WO1994022429A1 publication Critical patent/WO1994022429A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector

Definitions

  • the present invention relates to a liposomal composition for treatment of a tumor, and in particular, to a composition employing long- circulation liposomes.
  • Uncontrolled cell proliferation is a characteristic of a number of disease states.
  • Such growth is observed, for example, in benign and malignant tumors.
  • drugs used to treat cellular abnormalities characterized by uncontrolled cell growth target important biochemical steps or processes that are part of the cell growth cycle.
  • An object of the present invention is to provide a liposome composition for use in tumor treatment.
  • the composition includes liposomes containing an anti-tumor compound in liposome- entrapped form, a surface coating of polyethylene glycol chains, at a surface concentration thereof sufficient to extend the blood circulation time of the liposomes severalfold over that of liposomes in the absence of such coating, and antibodies or antibody fragments effective to bind specifically to tumor-associated antigens.
  • the polyethylene glycol chains contain, in a portion thereof, functionalized reactive groups at the chain ends to which the antibodies or antibody fragments are covalently attached.
  • the liposomes have sizes preferably in the range 0.05 to 0.3 microns, and for targeting to a solid tumor, have sizes preferably in a selected size range between 0.05 to 0.12 microns.
  • Fig. 1 illustrates a portion of a liposome in the liposome ocomposition of the invention, having antibodies or antibody fragments attached to the free ends of polyethylene glycol (PEG) chains carried on the liposome;
  • PEG polyethylene glycol
  • Fig. 2 shows steps in forming a PE derivatized by a PEG spacer chain having a maleimide group at its free end
  • Fig. 3 illustrates the preparation of a biotinylated PE-PEG for use in preparing liposomes with PEG-bound biotin;
  • Fig. 4 shows coupling of an antibody to PE derivatized with a PEG chain having a hydrazide moiety at its free end
  • Fig. 5 shows the coupling of an antibody to PE derivatized by a PEG chain having a reactive maleimide group at its free end;
  • Fig. 6 shows the coupling of an antibody to a liposome-attached PEG having a hydrazide group at its free end
  • Fig. 7 is a plot of drug residence time in the blood, expressed in terms of percent injected dose, as a function of hours after IV injection in rats, for liposomes containing 67 Gallium and a bound antibody IgG (•) or liposomes with no bound antibody (A) ;
  • Fig. 8 shows 125 dUrd uptake in normal and tumor-bearing DBA/2 mice (3/group) 45 days after i.v. injection of 2 x 10 s KLN-205 cells;
  • Fig. 9 shows survival times for DBA/2 mice inoculated i.v. with 2 x 10 s KLN-205 cells and treated on the 3rd day with 6 mg/kg of either free DOX (A) , liposomal DOX ( ⁇ ) , mAb-liposomal DOX ( ⁇ ) or mAb-liposomes ( ⁇ ) (12 ⁇ g mAb, no DOX) , control groups (•) were treated with sterile PBS.
  • Tumor-associated antigens refers to antigens that are expressed at higher levels in tumor tissue relative to healthy tissue. The term also refers to antigens expressed uniquely in tumor tissue.
  • Antibody fragments refers to the F ⁇ antibody domain carrying the antigen binding sites formed by cleavage of the antibody.
  • Fig. 1 illustrates the antibody-liposome composition of the present invention.
  • the figure shows a portion of the outer bilayer 10 of a liposome 12 having an outer surface 14.
  • the liposome may include additional bilayers.
  • the outer bilayer itself is composed of confronting lipid layers 10a and 10b which are the interior and exterior lipid layers, respectively, of the bilayer, each layer being composed of vesicle- forming lipids, such as phospholipids and cholesterol.
  • Methods for forming liposomes suitable for use in the composition are described below. More generally, the liposome is representative of a particle support forming part of the composition.
  • the composition includes an antibody or an antibody fragment, such as antibody 16, which is bound to the outer liposome surface by covalent attachment to hydrophilic polymer chains, such as chains 20, which are also carried on the liposome's outer surface.
  • the polymer chains form a polymer layer about the liposome surface which allows the liposomes to circulate in the bloodstream over an extended period of time compared to liposomes lacking the polymer coating.
  • the antigen recognition region, such as antigen recognition region 22, of the antibody molecule is accessible for binding to antigens at a target site.
  • the polymer coating on the liposome surface does not affect antigen-antibody interactions.
  • Antibody molecules suitable for use in the invention, and methods of their preparation are described below.
  • the polymer chains are preferably polyethylene glycol (PEG) chains having molecular weights between about 1,000 and 10,000 daltons. corresponding to polymer chain lengths of about 22 to 220 ethylene oxide units.
  • the polymer chains are covalently attached to the polar head groups of vesicle-forming lipids as described in co-owned U.S. Patent No. 5,013,556, herein incorporated by reference.
  • the polymer chain is attached to the liposome through the polar head group of a lipid, such as lipid 18, in the outer layer 10 of the liposome bilayer.
  • the chain contains a reactive functionalized group at its free end for coupling the antibody, by methods to be described.
  • the antibody in the composition is attached to the liposome outer surface by a polymer chain.
  • the antibody is positioned at the distal, or free, ends of the polymer chains, which in the illustration are shown to be of the same length.
  • the antibodies or antibody fragments are attached to a polymer chain of a different molecular weight or chain length, generally a shorter chain length.
  • This embodiment allows the antibody in the polymer layer to be positioned at a selected depth in the layer to increase or decrease the extent to which the antibody is buried in the polymer layer. For example, if the antibody is a xenogeneic antibody which elicits an immunogenic.
  • the antibody is preferably buried to hide immunogenic sites while retaining the antigen recognition region accessible for binding to a target site. If the antibody is nonimmunogenic, the antibody can be localized on the outer surface coating of polyethylene glycol chains. Functionalization of PEG chains for this purpose, referred to herein as a spacer chain, for attachment of an antibody is described below.
  • the antibody is a biotinylated antibody attached to the distal ends of liposome-attached polymer ends via a biotin- strepavidin (or biotin-avidin) linkage.
  • a DSPE-PEG-NH j is converted to DSPE-PEG-biotin.
  • each avidin molecule contains four high-affinity biotin binding sites and to one or more of these sites is attached the liposome bound biotin.
  • a biotinylated antibody which is derivatized by a biotin molecule.
  • the particle supports should be biodegradable, have surface chemical groups through which polymer chains of polypeptide molecules can be attached to the surface, and preferably have sizes in a selected size range between about 50-300 n .
  • Exemplary particle supports of this type include sized polylactic acid particles, or microcapsules formed of poly(amino acids) .
  • the liposomes of the present invention are generally composed of at least three types of lipid components.
  • a first type which will form the bulk of the liposome structure, includes any amphipathic lipids having hydrophobic and polar head group moieties, and which (a) can form spontaneously into bilayer vesicles in water, as exemplified by phospholipids, or (b) are stably incorporated into lipid bilayers, with its hydrophobic moiety in contact with the interior, hydrophobic region of the bilayer membrane, and its polar head group moiety oriented toward the exterior, polar surface of the membrane.
  • the vesicle-forming lipids of this type are preferably ones having two hydrocarbon chains, typically acyl chains, and a polar head group. Included in this class are the phospholipids, such as phosphatidylcholine (PC) , PE, phosphatidic acid (PA) , phosphatidylglycerol (PG) , phosphatidylinositol (PI) , and sphingomyelin (SM) , where the two hydrocarbon chains are typically between about 14-22 carbon atoms in length, and have varying degrees of unsaturation.
  • PC phosphatidylcholine
  • PE phosphatidic acid
  • PG phosphatidylglycerol
  • PI phosphatidylinositol
  • SM sphingomyelin
  • the above- described lipids and phospholipids whose acyl chains have a variety of degrees of saturation can be obtained commercially, or prepared according to published methods.
  • a second lipid component includes a vesicle- forming lipid which is derivatized with a polymer chain.
  • the vesicle-forming lipids which can be used are any of those described above for the first vesicle-forming lipid component.
  • Vesicle- forming lipids with diacyl chains, such as phospholipids, are preferred.
  • One exemplary phospholipid is phosphatidylethanola ine (PE) with a reactive amino group which is convenient for coupling to the activated polymers.
  • An exemplary PE is distearyl PE (DSPE) .
  • the preferred polymer in the derivatized lipid is polyethyleneglyc ⁇ l (PEG) , preferably as a PEG chain having a molecular weight between 1,000-10,000 da1tons, more preferably between 2,000 and 5,000 daltons.
  • PEG polyethyleneglyc ⁇ l
  • the polyethylene glycol chains provide a surface coating of hydrophilic chains sufficient to extend the blood circulation time of the liposomes in the absence of such a coating.
  • hydrophilic polymers which may be suitable include polyvinylpyrrolidone, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide, polydimethylacrylamide, polylactic acid, polyglycolic acid, and derivatized celluloses, such as hydroxymethylcellulose or hydroxyethylcellulose.
  • a third type of lipid component are vesicle- forming lipids which have been modified for coupling antibody molecules to the liposome outer surface.
  • These modified lipids may be of different types.
  • the modified lipid may contain a hydrophilic polymer spacer chain attached to the lipid.
  • the spacer chain as described above, has a different chain length than the polymer chains forming the liposome surface polymer coating for positioning the antibody at a selected depth in the polymer coating.
  • the hydrophilic polymer is typically end-functionalized for coupling antibodies to its functionalized end.
  • the functionalized end group is preferably a maleimide group for selective coupling to antibody sulfhydryl groups.
  • Suitable functionalized end groups include bromoacetamide and disulfide groups for reaction with antibody sulfhydryl groups, activated ester and aldehyde groups for reaction with antibody amine groups.
  • Hydrazide groups are reactive toward aldehydes, which can be generated on numerous biologically relevant compounds. Hydrazides can also be acylated by active esters or carbodiimide- activated carboxyl groups. Acyl azide groups reactive as acylating species can be easily 10 obtained from hydrazides and permit the attachment of amino containing ligands.
  • a preferred polymer in the derivatized lipid is polyethylene glycol (PEG) .
  • PEG polyethylene glycol
  • Other hydrophilic polymers which may be suitable for lipid derivatization include end-functionalized polyvinylpyrrolidone, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide, polydimethylacrylamide, polylactic acid, polyglycolic acid, and derivatized celluloses, such as hydroxymethylcellulose or hydroxyethylcellulose.
  • This polymer spacer chain is preferably shorter than the polymer chain forming the liposome surface polymer coating layer.
  • the spacer arm is generally of 100-5,000 daltons, preferably 600-4,000 daltons.
  • the phospholipid may be modified by a biotin molecule.
  • a biotin molecule to attach the antibody molecule to the biotinylated liposome surface, once the liposome is formed, the antibody molecule is also modified with biotin and then incubated in the presence of the avidin.
  • Biotinylated lipids such as biotinylated PE, are commercially available.
  • lipids may be modified by a substrate for use in binding a targeting molecule to a liposome surface.
  • substrates as exemplified with biotin, are relatively small, e .g. , less than about 5,000 daltons, to allow their incorporation into multilamellar liposomes with a minimum of disruption of the lipid bilayer structures.
  • the substrate is preferably one capable of binding irreversibly to a targeting 11 molecule, to ensure that the targeting molecule remains bound to the liposomes over its lifetime in the bloodstream.
  • the liposomes may include lipids that can stabilize a vesicle or liposome composed predominantly of phospholipids.
  • the most frequently employed lipid from this group is cholesterol at between 25 to 40 mole percent.
  • cholesterol at between 0 to 20 mole percent cholesterol in a bilayer, separate domains exist containing cholesterol and phospholipids and pure phospholipid (Mabrey) . These bilayers show an increased permeability to water (Tsong) . At mole percentages above 50% cholesterol starts destabilizing the bilayer.
  • Liposome-Entrapped Compound A variety of therapeutically active compounds are suitable for delivery by the liposome composition.
  • the compound is useful, preferably, for treatment of a tumor. More generally, the therapeutic compound in liposome-entrapped form is used to treat diseased cells accessible to liposome-entrapped compounds in the bloodstream.
  • One general class includes water soluble, liposome permeable compounds which are characterized by a tendency to partition into the aqueous compartment of the liposome composition, and to equilibrate over time into the outer bulk phase of the liposome composition.
  • Preferred drugs are those that have a low liposome permeability.
  • Representative drugs of this kind include cytarabine, cyclophosphamide, methotrexate, gentamicin, and bleomycins, among others. 12
  • a second general class of compounds are those which are water-soluble, but liposome impermeable. These compounds include peptide or protein molecules, such as peptide hormones, enzymes, enzyme inhibitors, and higher molecular weight carbohydrates. Representative compounds include peptide hormones, such as vasopressin, cytokines, such as interferons (alpha, beta, gamma) , interleukins, and colony stimulating factors (macrophage, granulocyte, granulocyte and macrophage), viral or bacterial vaccines, melanoma vaccine, streptokinase, or other anti-thrombolytic peptides, and superoxide dis utase.
  • peptide hormones such as vasopressin, cytokines, such as interferons (alpha, beta, gamma) , interleukins, and colony stimulating factors (macrophage, granulocyte, granulocyte and macrophage)
  • viral or bacterial vaccines mel
  • a third class of drugs are lipophilic molecules that tend to partition into the lipid bilayer phase of the liposomes, and which are therefore associated with the liposomes predominantly in a membrane-entrapped form.
  • the drugs in this class include adrenocorticosteroids, prostaglandins, amphotericin B, nitroglycerin, polymyxins, carmustine, dacarbazine, dexamethasone, daunomycin and doxorubicin.
  • the liposome-entrapped compound may also be an imaging agent for tracking progression of a disease, such as tumor metastasis.
  • Imaging agents include chelates of radionuclides, such as technetium-99, indium-Ill, and iodine-124.
  • the antibodies are monoclonal antibodies or antibody fragments, e .g. , F ⁇ fragments, which are used for targeting tumor-associated antigens in the treatment of cancer. These antibodies or antibody fragments are typically derived from hybridomas that show positive reactivity toward the tumor tissue and negative reactivity toward healthy tissue (Samuel) .
  • monoclonal antibodies are known which react with tumor-associated antigens.
  • the antibody may be a monoclonal antibody that reacts with a high-molecular mucin expressed on several types of human carcinoma (Slavin-
  • the antibody may be an antibody that targets an antigen of tumor vascular epithelium. This type of targeting may be applicable to many types of solid tumors since many tumors require a blood supply, and epithelial cells are readily accessible from the bloodstream (Burrows) .
  • the liposomes can be used, for example, for targeting spontaneous liver metastases by use of an antibody that binds to an antigen expressed on metastasizing liver cells, but not on normal liver tissue (Schmid) .
  • the antibodies may also be used to localize a liposome-entrapped compound at non-tumor cells.
  • the antibody may be used to target liposomes to sites of myocardial necrosis (Nedelman) . Liposome entrapped compounds administered to these site may be superoxide dismutase or antithrombolytic compounds for treatment of symptoms associated with myocardial infarction.
  • the antibody may also be used for targeting a virus or a bacterium, and the antibody recognizes an antigen associated with either virus or bacterium.
  • IgG j monoclonal antibodies, 174H.64 (mAb) were used to target a liposome- entrapped drug to lung tumor cells. These antibodies recognize a unique epitope on proliferating cells of murine lung squamous carcinoma, KLN-205, as well as of human and bovine squamous carcinoma (Samuel) . 14
  • This section describes the synthesis of some exemplary modified lipids for use in coupling antibodies or antibody fragments to a liposome surface. Also described are methods of preparing liposomes which incorporate the modified lipids, and for coupling antibodies to a liposome surface via the modified lipids.
  • Fig. 2 shows the synthesis of a DSPE derivatized with a PEG chain and having a maleimide group at the chain's free end.
  • PEG bis (amine) compound I
  • 2-nitrobenzene sulfonyl chloride compound II
  • TEA triethylamine
  • the compound is reacted with DSPE in TEA to form the derivatized PE lipid protected at one end with 2- nitrobenzyl sulfonyl chloride.
  • Fig. 3 shows the synthesis of a DSPE-PEG derivatized with a succinimide ester of biotin (compound VII) .
  • the biotinylated phospholipid (compound VIII) is incorporated into liposomes.
  • the liposomes are then incubated with avidin and biotinylated antibody.
  • a DSPE derivatized with a PEG chain having a hydrazide group at the chain's free end may be synthesized, as illustrated in Fig. 4.
  • a hydroxy acid derivative (IX) is prepared from PEG using ethyl isocyanatoacetate for partial introduction of a urethane-linked glycine residue.
  • the initial product is treated with base to remove the terminal ethyl ester group, and product IX is isolated by ion-exchange chromatography.
  • the liposomes may be prepared by a variety of techniques, such as those detailed in Szoka et al , 1980.
  • Multilamellar vesicles can be formed by simple lipid-film hydration techniques. In this procedure, a mixture of liposome-forming lipids of the type detailed above dissolved in a suitable organic solvent is evaporated in a vessel to form a thin film, which is then covered by an aqueous medium. The lipid film hydrates to form MLVs, typically with sizes between about 0.1 to 10 microns.
  • liposomes are prepared by vortexing dried lipid films in a buffered aqueous solution (Olson) .
  • Liposome compositions are typically prepared with lipid components present in a molar ratio of about 30-75 percent vesicle-forming lipids, 25-40 percent cholesterol, 1-20 percent polymer- derivatized lipid, and 0.01-10 mole percent of the lipid derivative employed for antibody coupling.
  • One exemplary liposome formulation includes hydrogenated soy phosphatidylethanolamine (HSPE) , cholesterol (CH) , DSPE-PEG at a molar ratio of 2:1:0.1.
  • the composition also includes 0.05 mole percent phosphatidylethanolamine derivatized with biotin (biotin-PE) .
  • Another exemplary liposome formulation includes hydrogenated soy phosphatidylethanolamine (HSPE) , cholesterol (CH) , and DSPE-PEG at a molar ratio of 2:1:0.1.
  • the composition also includes 1 mole percent DSPE-PEG derivatized with hydrazide (DSPE-PEG-Hz) .
  • a therapeutic drug is incorporated into liposomes by adding the drug to the vesicle- forming lipids prior to liposome formation, as described below, to entrap the drug in the formed liposome. If the drug is hydrophobic the drug is added directly to the hydrophobic mixture. If the drug is hydrophilic the drug can be added to the aqueous medium which covers the thin film of evaporated lipids. Alternatively, the drug may be incorporated into preformed liposomes by active transport mechanisms. Typically, in this case drug is taken up in liposomes in response to a potassium or hydrogen ion concentration differential (Mayer, 1986; Mayer 1989).
  • One effective sizing method for REVs and MLVs involves extruding an aqueous suspension of the liposomes through a series of polycarbonate membranes having a selected uniform pore size in the range of 0.03 to 0.2 micron, typically 0.05, 0.08, 0.1, or 0.2 microns.
  • the pore size of the membrane corresponds roughly to the largest sizes 17 of liposomes produced by extrusion through that membrane, particularly where the preparation is extruded two or more times through the same mem ⁇ brane.
  • Homogenization methods are also useful for down-sizing liposomes to sizes of lOOnm or less (Martin 1990) .
  • Antibodies may be attached to a liposome by covalent methods as have been described.
  • a derivatized lipid containing an end-functionalized polyethylene glycol chain is incorporated into liposomes. After liposome formation, the end- functionalized group can react with an antibody for antibody coupling to a liposome.
  • an antibody-lipid derivative may be first formed and then incorporated into a liposome.
  • an antibody is coupled to the maleimide group of a free DSPE-PEG molecule.
  • the antibody-coupled DSPE-PEG molecule is then employed to form vesicles.
  • the end- functionalized group is a maleimide group which is preferentially reactive with sulfhydryl groups.
  • Antibodies contain sulfhydryl groups which react at the maleimide group forming a thioether linkage to generate compound XII. Details of the reactions are given in Example 1.
  • the polymer end-functionalized group is a hydrazide group (see Figure 4 discussed above) .
  • the hydrazide can be coupled to the antibody through the carbohydrate moieties present in the antibody, as detailed in Figure 6 and Example l.VIII. Briefly, antibody hydroxyl groups are oxidized to aldehydes by mild periodate oxidation. The oxidized protein is then 18 added to liposomes containing DSPE-PEG-Hz and incubated overnight. Unbound antibodies are then separated from antibody-liposomes by gel filtration.
  • antibodies can be attached to the PEG chain free ends without a significant loss in the blood circulation lifetime of the liposomes. This allows the antibody-coated liposomes to circulate for the time necessary to reach remote tumor sites and to localize at the sites through antibody-antigen specific interactions. As a result, a significant therapeutic enhancement in tumor treatment over long-circulating liposomes in the absence of surface attached antibodies is possible.
  • Liposomes like those above except containing entrapped 67 Gallium were prepared and administered to rats to measure the blood circulation time, as described in Example 2(11).
  • the levels of liposome-entrapped 67 GaIlium were measured at regular intervals following administration of the two liposome formulations and the results are shown in Fig. 7.
  • both liposome formulations gave good blood circulation lifetime, with more than 10% of the injected marker being retained in the bloodstream after 24 hours.
  • it is known from similar studies (Martin 1993) carried out with liposomes not containing PEG that standard, non-PEG coated liposomes show only about 5% marker retention in the blood 3 hours or less after iv administration and no measurable liposome label at 24 hours.
  • An antibody-liposome composition was prepared to contain on their outer surface IgG j monoclonal antibodies 174H.64 (mAb), which recognizes a unique epitope on proliferating cells of murine lung squamous carcinoma, KLN-205, as well as those for human and bovine squamous carcinoma.
  • the liposomes were tested for their therapeutic effectiveness for treatment of KLN-205 carcinoma.
  • the KLN-205 carcinoma lodges in the lung of DBA2 mice within 3 days following intravenous injection (Kaneko) .
  • Fig. 8 shows the growth inhibitory effect of doxorubicin intravenous injections as reflected by a decrease in deoxyuridine uptake by tumor cells in the lung.
  • mice were injected intravenously with KLN-205 cells. At three days post-injection the mice were treated by administering intravenously a single dose of doxorubicin (6 mg/kg body weight) .
  • Doxorubicin was administered in either free form (not encapsulated in liposomes) (DOX) , encapsulated in liposomes lacking the antibody (liposomal DOX) , or encapsulated in antibody-liposome compositions (mAb liposomal DOX) .
  • Uridine uptake into lung has been established to be directly proportional to the number of intravenous injections of KLN-205 tumor cells in the range of 10 5 to 10 6 injected cells and reflects the number of highly proliferating cells in a tissue. Uridine uptake in lungs from normal mice in the absence of tumor is low.
  • a single injection of mAb-liposomal DOX resulted in an 80% reduction in the growth of lung tumors as measured by radiolabelled deoxyuridine uptake.
  • Single injections of liposomal DOX resulted in a 65% reduction in the growth of the lung tumors.
  • Administration of free doxorubicin resulted in only a 40% reduction in lung tumor growth.
  • Example 4 histopathological studies were also performed as described in Example 4. These studies showed that the presence of tumor nodules was minimal after mAb-liposomal DOX administration. Animals that received single injections of liposomal DOX showed fewer nodules than those that received free DOX or no treatment. The number of discrete tumor foci/linear cm of lung were counted for both the right and left lungs for 1 or 2 mice from each treatment group of 5 mice, and mean tumor diameters were determined as compiled in Table 2. The number of tumor foci/linear cm was negligible for mice receiving mAb-liposomal DOX.
  • Liposome uptake in the lung was also examined and is described in Example 5. Uptake of liposomes containing radiolabeled tyraminylinulin in mAb-liposome-entrapped form by tumor lung tissue was greater than for liposomes lacking antibody bound at the liposome surface.
  • the results obtained indicate that liposomes containing entrapped doxorubicin, lipids derivatized with PEG, such as PEG-DSPE, and containing an antibody on the liposomes' outer surface (mAb-liposomal DOX) are valuable for increasing the therapeutic effectiveness of doxorubicin administration to a site in a subject.
  • the method of the present invention is likely applicable to the targeting of other therapeutic compounds to tumor sites, or other target sites.
  • the above described antibody-liposome composition containing an anti-tumor compound in liposome- entrapped form, is used for tumor treatment.
  • the antibody-liposome enhances the therapeutic efficacy of the compound by localizing the liposome, and the anti-tumor compound, selectively at the tumor site.
  • doxorubicin administered parenterally in antibody-liposome entrapped form substantially increased the survival time of mice with lung tumor.
  • Fig. 9 shows survival data for mice receiving various treatments of doxorubicin at doses of 6 mg/kg body weight, as described in
  • Example 3 The mean survival time (MST) for mice treated with mAb liposomal DOX, that died from their tumors was 99.2 ⁇ 36.1 days and was substantially longer than the MST for untreated mice (52.0 ⁇ 5.8 days).
  • the group treated with doxorubicin in mAb-liposome entrapped form showed a 50% survival rate.
  • the method of the present invention is of utility for the treatment of both "solid" tumors and blood-born tumors.
  • a solid tumor is defined as one that grows in an anatomical site outside the bloodstream (in contrast, for example, to blood-born tumors such as leukemias) and requires the formation of small blood vessels and capilla ⁇ ries to supply nutrients, etc. to the growing tumor mass.
  • the anti-tumor compound which may be used is any compound, including the ones listed below, which can be stably entrapped in liposomes at a suitable loading factor and administered at a therapeutically effective dose (indicated below in parentheses after each compound) .
  • amphipathic anti-tumor compounds such as the plant alkaloids vincristine (1.4 mg/m 2 ) , vinblastine (4- 18 mg/m 2 ) and etoposide (35-100 mg/m 2 ) , and the anthracycline antibiotics including doxorubicin (60-75 mg/m 2 ) , epirubicin (60-120 mg/m 2 ) and daunorubicin (25-45 mg/m 2 ) .
  • the water-soluble anti-metabolites such as methotrexate (3 mg/m 2 ) , cytosine arabinoside (100 mg/m 2 ) , and fluorouracil (10-15 mg/kg)
  • the antibiotics such as bleomycin (10-20 units/m 2 ) , mitomycin (20 mg/m 2 ), plicamycin (25-30 ⁇ g/m 2 ) and dactinomycin (15 ⁇ g/m 2 )
  • the alkylating agents including cyclophosphamide (3-25 mg/kg), thiotepa (0.3-0.4 mg/Kg) and BCNU (150-200 mg/m 2 ) are also useful in this context.
  • the liposomes may contain encapsulated tumor-therapeutic peptides and protein drugs, such as IL-2, and/or TNF, and/or immunomodulators, such as M-CSF, which are present 24 alone or in combination with anti-tumor drugs, such as an doxorubicin.
  • IL-2 IL-2
  • TNF tumor-therapeutic peptides and protein drugs
  • immunomodulators such as M-CSF
  • an antibody modified by a ligand molecule such as a biotinylated antibody
  • a ligand molecule such as a biotinylated antibody
  • liposomes containing a liposome-entrapped compound, and a surface-bound anti-ligand molecule, such as avidin are administered parenterally. Liposomes with the surface-bound avidin will be retained at target sites by biotin molecules covalently attached to the antibodies.
  • multivalent species capable of binding multiple antibodies may be administered between about 24 to 48 hours after administration of the biotinylated antibodies to accelerate clearance of the antibodies from the bloodstream.
  • These multivalent species may be empty liposomes having surface-bound avidin, but not containing the liposome-entrapped compound.
  • the empty liposomes may or may not have a hydrophilic polymer surface layer.
  • the multivalent species may be avidin molecules.
  • multivalent species serve to chase nonspecifically-bound biotinylated antibodies from sites in the bloodstream.
  • liposomes containing the therapeutic compound in liposome-entrapped form the surface-bound anti- ligand molecules, such as avidin, and the PEG layer on the liposome surface are administered.
  • the chase with the multivalent species will prevent binding of liposomes containing liposome entrapped-drug at non-specific sites and 25 will maximize the specificity of therapeutic compound targeting in vivo.
  • the present method can be employed for improved targeting of an imaging agent to a tumor, for tumor diagnosis.
  • the imaging agent typically a radioisotope in chelated form, or a paramagnetic molecule
  • the imaging agent is entrapped in liposomes, which are then administered IV to the subject being examined.
  • the subject is then monitored, for example by gamma scintillation radiography in the case of the radioisotope, or by nuclear magnetic resonance (NMR) in the case of the paramagnetic agent, to detect regions of local uptake of the imaging agent.
  • NMR nuclear magnetic resonance
  • antibody-liposomes would be useful for delivery of anti-infective compounds to regions of infections. Sites of infection, like tumors, often exhibit specific antigens or antigens expressed at higher levels that may be targeted by the antibody- liposome compositions. It is expected that antibody-liposomes containing antibiotics (such as aminoglycosides, cephalosporins, and beta lactams) would improve compound localization at sites of infection, thereby improving the therapeutic index of such agents, particularly ones which exhibit dose-related toxicities, such as the aminoglycosides.
  • antibiotics such as aminoglycosides, cephalosporins, and beta lactams
  • IgG monoclonal antibody 174H.64 (mAb) directed against mammalian squamous carcinoma was 26 a generous gift of Biomira, Inc. (Edmonton, AB) .
  • Hydrogenated soy phosphatidylcholine (HSPC) was obtained from Asahi Chemicals, Japan.
  • Cholesterol (CH) was purchased from Sigma Chemicals (St. Louis, MO) .
  • Example 2 Biodistribution of Antibody-Liposomes The biodistribution and blood circulation lifetime of liposomes containing surface-bound antibodies was compared to that of liposomes lacking surface-bound antibodies.
  • the antibody- liposomes were composed of HSPC:CH:PEG hydrazide, at a 2:1:0.1 molar ratio, and sheep IgG covalently linked to PEG chain.
  • Liposomes lacking surface- bound antigens were liposomes composed of HSPC:CH:PEG at a 2:1:0.1 molar ratio and liposomes composed of HSPC:CH:PEG hydrazide. The average diameter of the liposomes was between 110 and 120 nanometers.
  • the liposomes contained 125 I-tyraminylinulin in liposome-entrapped form (Example 2(1)).
  • the liposomes contained 67 Gallium in liposome-entrapped form.
  • the antibody-liposomes were prepared as described in Example l.VIII.
  • mice Female CD(ICR) BR (outbred) mice in the weight range of 23-30 grams were obtained from Charles River Canada (St. Constant, QUE) , and maintained in standard housing. Mice (three per group) were given a single bolus injection with 0.2 ml of liposomes containing approximately 10° 125 I-T1 cpm and 0.5 micromole phospholipid, and approximately 10 micrograms antibody, where applicable. Some groups of mice received injection of free radiolabelled TL. Injections were performed by intravenous injection via the tail vein. After specified periods of time, animals were anesthetized with halothane (M.T.C. Pharmaceutical, Ontario) and sacrificed by cervical dislocation.
  • halothane M.T.C. Pharmaceutical, Ontario
  • DBA2 mice (Jackson Laboratories) were injected i.v. with 2 x 10 5 KLN-205 cells. At 3 days post-injection of KLN-205 cells, the mice were injected i.v. with single injections of either 0.2 ml phosphate-buffered saline (PBS) (untreated controls) or with 6 mg/kg of either free DOX, 6 mg/kg of DOX entrapped in HSPC:CH:PEG- DSPE liposomes (liposomal DOX) , 6 mg/kg of DOX entrapped in HSPC:CH:PEG-DSPE liposomes containing attached antibody 174H.64 (mAb-liposomal DOX) or mAb-liposomes (11-39 ⁇ g mAb) lacking DOX, all in 0.2 ml of sterile saline.
  • PBS 0.2 ml phosphate-buffered saline
  • DOX free DOX
  • mice On the 45th day after injection, mice were injected with 2 ⁇ Ci each of 125 I-dUrd and 4 hr later the lungs were removed, cut into small pieces, washed with 10% trichloroacetic acid and counted in a gamma counter.
  • Liposomal DOX 10 0.31 ⁇ 0.06 19 0.39 ⁇ 0.23 mAb-liposomal DOX 0.3 0.22 0.7 0.18, 0.26
  • Uptake of liposomes labelled with 125 i- tyraminylinulin ( 125 I-TI) into lung in DBA/2 mice (3/group) at 15 minutes post-injection was determined. Uptake experiments provide a measure of uptake of intact liposomes. Liposome uptake was examined at 3 days and 45 days after i.v. injection of 2 x 10 s KLN-205 cells. Experimental groups were composed of tumor-free (control) animals receiving either HSPC:CH:PEG-DSPE or mAb- HSPC:CH:PEG-DSPE liposomes (2:1:0.1 molar ratio, no drug) , or tumor-bearing animals receiving similar liposomes.
  • Liposome uptake experiments were performed to confirm specific localization of the liposomes to the lungs.
  • the uptake of liposomes and mAb- liposomes into lung in tumor bearing mice at 3 days post-injection was 29.4 ⁇ 4.1 and 72.7 ⁇ 26.9 cpm/mg total lung tissue, respectively. This compares with 27.4 ⁇ 10.6 and 41.6 ⁇ 29.6 cpm/mg total lung tissue for tumor-free lungs.
  • the uptake of mAb liposomes was 121.9 ⁇ 35.4, as compared with tumor-free mice (42.9 ⁇ 6.2 cpm/mg total lung tissue) .
  • Lung uptake at 45 days postinjection of tumor was 5.0 ⁇ 1.1% of in vivo mAb liposomes for tumor-bearing mice compared to 1.3 ⁇ 0.2% for tumor-free mice at 24 hours post-injection of liposomes.
  • the increased uptake of mAb liposomes suggests that they are able to bind to proliferating tumor cells localized in the lung.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention se rapporte à une composition de liposomes destinée au traitement d'une tumeur chez un sujet. La composition comprend des liposomes (12) contenant un composé antitumoral sous une forme piégée par les liposomes, et comportant en surface une couche de chaînes de polyéthylène glycol (20), en une concentration de surface suffisante pour multiplier plusieurs fois le temps de circulation dans le sang desdits liposomes par rapport à celui de liposomes dépourvus de cette couche PEG. Des anticorps ou fragments d'anticorps (16), efficaces pour se lier spécifiquement aux antigènes associés à la tumeur, présents sur le site tumoral, sont fixés aux extrémités libres d'une partie des chaînes polymères. Une composition de liposomes a une granulométrie prédominante comprise entre 0,05 et 0,12 microns, renferme de la doxorubicine sous forme piégée, et contient, sur les extrémités libres des chaînes PEG, un anticorps monoclonal spécifiquement dirigé contre des cellules fortement prolifératives d'un épithélioma épidermoïde bronchique.
PCT/US1994/003457 1993-03-31 1994-03-30 Procede de traitement d'une tumeur solide WO1994022429A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU65272/94A AU6527294A (en) 1993-03-31 1994-03-30 Solid-tumor treatment method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/040,544 US5527528A (en) 1989-10-20 1993-03-31 Solid-tumor treatment method
US08/040,544 1993-03-31

Publications (1)

Publication Number Publication Date
WO1994022429A1 true WO1994022429A1 (fr) 1994-10-13

Family

ID=21911563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/003457 WO1994022429A1 (fr) 1993-03-31 1994-03-30 Procede de traitement d'une tumeur solide

Country Status (3)

Country Link
US (1) US5527528A (fr)
AU (1) AU6527294A (fr)
WO (1) WO1994022429A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0657463A1 (fr) * 1993-12-06 1995-06-14 Nof Corporation Dérivés de phospholipides et vésicule les contenant
US5463066A (en) * 1993-12-06 1995-10-31 Nof Corporation Phospholipid derivative and reactive vesicle-forming agent
WO1996034598A1 (fr) * 1995-05-03 1996-11-07 Polymasc Pharmaceuticals Plc Inclusion dans des tissus
WO1998008489A1 (fr) * 1996-08-26 1998-03-05 Transgene S.A. Complexes acides nucleiques/lipides cationiques
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
EP0903152A3 (fr) * 1997-09-17 1999-07-07 Mitsubishi Chemical Corporation Dérivés polymeriques aquasolubles et complexes les contenant
WO1999033493A1 (fr) * 1997-12-23 1999-07-08 Inex Pharmaceuticals Corporation Oligomeres polyamidiques
EP0912198A4 (fr) * 1996-04-18 2000-04-12 Univ California Immunoliposomes optimisant l'internalisation dans des cellules cibles
WO2001011069A1 (fr) 1999-08-06 2001-02-15 Celltech R&D Limited Complexes de lipide congeles/decongeles et leur preparation
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
WO2001060417A3 (fr) * 2000-02-21 2002-02-07 Anticancer Therapeutic Inv Sa Liposomes therapeutiques radioactifs
EP1170018A4 (fr) * 1999-03-17 2002-04-17 Mitsubishi Chem Corp Complexe lie par un ligand
US6673364B1 (en) 1995-06-07 2004-01-06 The University Of British Columbia Liposome having an exchangeable component
US6734171B1 (en) 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
WO2005049091A3 (fr) * 2003-11-13 2006-11-09 Elan Pharma Int Ltd Compositions comprenant des anticorps et procedes d'utilisation de celles-ci pour l'administration ciblee d'un agent actif nanoparticulaire
EP2015066A1 (fr) * 1997-11-03 2009-01-14 Roche Diagnostics GmbH Biomolécules dérivés du polyéthylèneglycole et leur utilisation dans des procédés de détection hétérogènes
WO2012117385A2 (fr) 2011-03-03 2012-09-07 WROCŁAWSKIE CENTRUM BADAŃ EIT+ Sp z o.o. Formulation liposomale comprenant une substance active antitumorale, procédé de préparation et compositions pharmaceutiques la comprenant
US20220125728A1 (en) * 2020-10-22 2022-04-28 Rutgers, The State University Of New Jersey Strategies to Enhance Lung Cancer Treatment

Families Citing this family (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US20010051183A1 (en) * 1989-10-20 2001-12-13 Alza Corporation Liposomes with enhanced circulation time and method of treatment
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
US6180134B1 (en) * 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5834012A (en) * 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
US7166295B1 (en) 1995-05-26 2007-01-23 Meir Strahilevitz Methods of treatment and diagnostic visualization, particularly in cancer
US6420549B1 (en) 1995-06-06 2002-07-16 Isis Pharmaceuticals, Inc. Oligonucleotide analogs having modified dimers
US6107102A (en) * 1995-06-07 2000-08-22 Regents Of The University Of California Therapeutic microdevices and methods of making and using same
EP0832446A1 (fr) * 1995-06-07 1998-04-01 The Regents Of The University Of California Microelements a usage therapeutique et leurs procedes d'obtention et d'utilisation
US6821506B2 (en) 1995-06-08 2004-11-23 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
US5780010A (en) * 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20070275921A1 (en) * 1996-06-06 2007-11-29 Isis Pharmaceuticals, Inc. Oligomeric Compounds That Facilitate Risc Loading
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
AU5451598A (en) * 1996-11-22 1998-06-10 Regents Of The University Of California, The Transport of liposomes across the blood-brain barrier
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
CN1297480A (zh) 1997-02-21 2001-05-30 基因技术股份有限公司 抗体片段－聚合物偶联物和人源化的抗白细胞介素－8单克隆抗体
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
WO1998044910A1 (fr) 1997-04-09 1998-10-15 Philipp Lang NOUVELLE TECHNIQUE DE CONTROLE DE L'ADMINISTRATION DE MEDICAMENTS NON VULNERANTE $i(IN VIVO)
US6083923A (en) * 1997-10-31 2000-07-04 Isis Pharmaceuticals Inc. Liposomal oligonucleotide compositions for modulating RAS gene expression
US7005504B2 (en) * 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6593294B1 (en) * 1998-04-27 2003-07-15 Opperbas Holding B.V. Pharmaceutical composition comprising Factor VIII and neutral liposomes
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US20050084524A1 (en) * 1998-09-30 2005-04-21 Alza Corporation Method for potentiating activity of a chemotherapeutic drug
US6638727B1 (en) 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
WO2001005433A2 (fr) * 1999-07-14 2001-01-25 Board Of Regents, The University Of Texas System Methodes et compositions pour la liberation et la retention d'agents actifs dans des ganglions lymphatiques
CA2393595A1 (fr) * 1999-12-10 2001-06-14 Gigi Chiu Compositions d'excipient a base de lipides ayant des fonctions de reaction au moyen d'une surface protegee
DE19961277A1 (de) * 1999-12-18 2001-06-21 Cognis Deutschland Gmbh Verwendung von nanoskaligen Polymeren
DE19961939A1 (de) * 1999-12-22 2001-06-28 Cognis Deutschland Gmbh Verwendung von nanoskaligen kationischen Verbindungen
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US20030176385A1 (en) * 2000-02-15 2003-09-18 Jingfang Ju Antisense modulation of protein expression
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
US7179449B2 (en) * 2001-01-30 2007-02-20 Barnes-Jewish Hospital Enhanced ultrasound detection with temperature-dependent contrast agents
JP2004525916A (ja) * 2001-03-08 2004-08-26 ターゲサム・インコーポレーテッド 安定化された治療剤および撮像剤
EP1395243A2 (fr) * 2001-05-31 2004-03-10 SkyePharma Inc. Encapsulation de nanosuspensions dans des liposomes et des microspheres
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
KR20060125923A (ko) 2001-06-20 2006-12-06 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
EP1404698A4 (fr) 2001-06-21 2004-12-22 Isis Pharmaceuticals Inc Modulation anti-sens de l'expression de la superoxyde dismutase 1 soluble
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
DE60238143D1 (de) 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
EP2270231A3 (fr) 2001-10-09 2011-04-27 ISIS Pharmaceuticals, Inc. Modulation par antisense de l'expression de l'insulin-like growth factor binding protein 5
US20030228319A1 (en) 2002-04-16 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002368202B2 (en) 2001-11-02 2008-06-05 Insert Therapeutics, Inc Methods and compositions for therapeutic use of RNA interference
EP1465590B1 (fr) * 2001-11-02 2008-03-26 The Governors Of The University Of Alberta Formulations contenant un lipide-polyethylene glycol
US20040219201A1 (en) * 2001-12-06 2004-11-04 Yechezkel Barenholz Tempamine compositions and methods of use
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
MXPA04006554A (es) 2002-01-02 2005-03-31 Genentech Inc Composiciones y metodos para diagnostico y tratamiento de tumor.
US6696082B2 (en) * 2002-01-08 2004-02-24 Mccully Kilmer S. Enhanced liposomal thioretinaco ozonide compositions and liposomal carrier
US20030180712A1 (en) 2002-03-20 2003-09-25 Biostratum Ab Inhibition of the beta3 subunit of L-type Ca2+ channels
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
FR2840532B1 (fr) * 2002-06-11 2005-05-06 Ethypharm Sa Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s)
AR036316A1 (es) * 2002-08-29 2004-08-25 Monte Verde S A Una composicion farmaceutica de liposomas de tamano pequeno y metodo de preparacion
CA2498777C (fr) 2002-09-13 2015-01-13 Replicor, Inc. Oligonucleotides antiviraux non complementaires de sequence
AU2003278957A1 (en) 2002-09-26 2004-04-23 Amgen, Inc. Modulation of forkhead box o1a expression
EP2957568B1 (fr) 2002-11-05 2016-12-21 Ionis Pharmaceuticals, Inc. Compositions comprenant en alternance des nucléosides 2'-modifiées destinées à être utilisées dans la modulation génique
WO2004044138A2 (fr) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Composes oligomere chimeres et leur utilisation dans la modulation genique
WO2004044181A2 (fr) 2002-11-13 2004-05-27 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression d'apolipoproteine b
DK1569695T3 (da) 2002-11-13 2013-08-05 Genzyme Corp Antisense-modulering af apolipoprotein-b-ekspression
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
DE60329627D1 (de) * 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
EP1597366B1 (fr) 2003-02-11 2012-11-21 Antisense Therapeutics Ltd Modulation de l'expression du recepteur du facteur de croissance i analogue a l'insuline
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
WO2004082626A2 (fr) * 2003-03-18 2004-09-30 Ethicon, Inc. Diagnostic et traitement faisant appel a un inhibiteur de l'aromatase
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
JP2006523683A (ja) * 2003-04-15 2006-10-19 オッパーバス・ホールディング・ビー・ブイ タンパク質及び／またはポリペプチド及びコロイド粒子を含む医薬組成物
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
AU2004231740A1 (en) * 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Ofnew York Desmoglein 4 is a novel gene involved in hair growth
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
EP2241572A3 (fr) 2003-06-03 2011-04-06 Eli Lilly And Company Modulierung der Survivin-Expression
EP2530157B1 (fr) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Composés oligomères et compositions à utiliser dans la modulation de miARNs
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US8986731B2 (en) * 2003-08-26 2015-03-24 Biolitec Pharma Marketing Ltd Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy
US20070123480A1 (en) * 2003-09-11 2007-05-31 Replicor Inc. Oligonucleotides targeting prion diseases
US7425544B2 (en) 2003-09-18 2008-09-16 Eli Lilly And Company Modulation of eIF4E expression
PL1678194T3 (pl) 2003-10-10 2014-01-31 Alchemia Oncology Pty Ltd Modulowanie syntezy i degradacji hialuronianu w leczeniu choroby
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
DE602004021713D1 (de) * 2003-11-14 2009-08-06 Het Nl Kanker I The Netherland Pharmazeutische formulierungen mit kurzketten-sphingolipiden und ihre verwendung
EP2161283B1 (fr) 2003-11-17 2014-06-04 Genentech, Inc. Compositions comprenant des anticorps contre le CD79b, couplés à des inhibiteurs de croissance ou à des agents cytotoxiques, et procédés pour le traitement de tumeurs d'origine hématopoïétique
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20050164271A1 (en) 2004-01-20 2005-07-28 Sanjay Bhanot Modulation of glucocorticoid receptor expression
US7468431B2 (en) 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US20070053845A1 (en) * 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
US20050266067A1 (en) * 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8790919B2 (en) 2004-03-15 2014-07-29 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of RNA by RNase H
AU2005231692B2 (en) * 2004-03-26 2011-01-27 Curis, Inc. RNA interference modulators of Hedgehog signaling and uses thereof
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
EP1766071A4 (fr) * 2004-06-03 2009-11-11 Isis Pharmaceuticals Inc Composition a double brin comprenant des brins différentiellement modifiés utilisés dans la modulation génétique
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
ATE514776T1 (de) 2004-10-05 2011-07-15 California Inst Of Techn Aptamer-regulierte nukleinsäuren und verwendungen davon
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
US20060281680A1 (en) 2005-03-10 2006-12-14 Genentech, Inc. Methods and compositions for modulating vascular integrity
US20070065359A1 (en) * 2005-03-14 2007-03-22 Shiladitya Sengupta Nanocells for diagnosis and treatment of diseases and disorders
ATE541928T1 (de) 2005-03-31 2012-02-15 Calando Pharmaceuticals Inc Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
US20070160658A1 (en) * 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
WO2007062380A2 (fr) 2005-11-21 2007-05-31 Isis Pharmaceuticals, Inc. MODULATION DE L'EXPRESSION D’eIF4E-BP2
ES2453380T3 (es) 2006-01-26 2014-04-07 Isis Pharmaceuticals, Inc. Composiciones y utilizaciones dirigidas hacia la huntingtina
CA2647277A1 (fr) 2006-04-05 2007-11-08 Genentech, Inc. Methode d'utilisation du boc/cdo pour moduler l'emission des signaux du hedgehog
CA2651031A1 (fr) * 2006-05-03 2007-11-08 Baltic Technology Development, Ltd. Agents antisens combinant un oligonucleotide modifie par une base fortement liee et une nuclease artificielle
US20070264322A1 (en) * 2006-05-10 2007-11-15 Huang Ken S Method for making liposomes conjugated with temperature-sensitive ligands
US20090209625A1 (en) * 2006-05-23 2009-08-20 Sanjay Bhanot Modulation of chrebp expression
WO2008011473A2 (fr) 2006-07-19 2008-01-24 Isis Pharmaceuticals, Inc. Compositions et leurs utilisations liées à l'hbxip
US20080213349A1 (en) * 2006-09-11 2008-09-04 Deepak Ramesh Thakker Liposome Complexes Containing Pharmaceutical Agents and Methods
US8158595B2 (en) * 2006-11-09 2012-04-17 California Institute Of Technology Modular aptamer-regulated ribozymes
EP2118118B1 (fr) * 2007-01-19 2017-09-27 Exiqon A/S Apport cellulaire médié d'oligonucléotides de lna
EP2114981B1 (fr) 2007-01-29 2013-05-08 Isis Pharmaceuticals, Inc. Composés et méthodes pour moduler l'expression des proteines
EP2436781B1 (fr) 2007-02-22 2015-10-07 Genentech, Inc. Méthode de détection d'une maladie intestinale inflammatoire
US20090163698A1 (en) * 2007-05-11 2009-06-25 John Joseph Grigsby Method for Preparing Antibody Conjugates
JP2010527618A (ja) 2007-05-24 2010-08-19 アメリカ合衆国 ヌクレオシドサルベージ経路を通しての核内タンパク質伝達
US20090082217A1 (en) * 2007-07-16 2009-03-26 California Institute Of Technology Selection of nucleic acid-based sensor domains within nucleic acid switch platform
US20120165387A1 (en) 2007-08-28 2012-06-28 Smolke Christina D General composition framework for ligand-controlled RNA regulatory systems
US8367815B2 (en) * 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US8865667B2 (en) * 2007-09-12 2014-10-21 California Institute Of Technology Higher-order cellular information processing devices
AU2008307482B2 (en) 2007-10-02 2012-07-12 Amgen Inc. Increasing erythropoietin using nucleic acids hybridizable to micro-RNA and precursors thereof
BRPI0819193A2 (pt) * 2007-11-05 2017-05-23 Baltic Tech Dev Ltd uso de oligonucleotídeos com bases modificadas na hibridização de ácidos nucleicos.
US20110160642A1 (en) * 2007-11-15 2011-06-30 Wolfgang Neuberger Pegylated liposomal formulations for photodynamic treatment of inflammatory diseases
EP2224963A1 (fr) * 2007-11-19 2010-09-08 CeramOptec GmbH Composés pegylés pour la dégénérescence maculaire liée à l'âge
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
JP2011516065A (ja) 2008-04-04 2011-05-26 カランド ファーマシューティカルズ， インコーポレイテッド Ｅｐａｓ１阻害剤の組成物および使用
WO2009142892A1 (fr) * 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Procédés et compositions comprenant de nouveaux lipides cationiques
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
AU2009275387B2 (en) 2008-08-25 2010-07-08 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US8796443B2 (en) 2008-09-22 2014-08-05 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
EP2370580B1 (fr) 2008-12-04 2019-09-11 CuRNA, Inc. Traitement de maladies liées à sirtuine 1 (sirt1) par inhibition d'un transcrit antisens naturel de sirtuine 1
ES2629630T3 (es) 2008-12-04 2017-08-11 Curna, Inc. Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
EP2370582B1 (fr) 2008-12-04 2017-05-10 CuRNA, Inc. Traitement de maladies liées à un gène suppresseur de tumeur par inhibition d'un transcrit antisens naturel du gène
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2010090762A1 (fr) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Duplexes d'arn avec régions de nucléotide phosphorothioate à brin unique pour fonctionnalité supplémentaire
PT2396038E (pt) 2009-02-12 2016-02-19 Curna Inc Tratamento das doenças associadas com o factor neurotrófico derivado do cérebro (bdnf) por inibição do produto antisenso natural da transcrição para bdnf
CN102439149B (zh) 2009-02-12 2018-01-02 库尔纳公司 通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
CA2754749C (fr) 2009-03-04 2019-04-30 Opko Curna, Llc Traitement de maladies liees a sirtuine 1 (sirt1) par inhibition d'un produit de transcription antisens naturel de sirt 1
CN102482677B (zh) 2009-03-16 2017-10-17 库尔纳公司 通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病
WO2010107740A2 (fr) 2009-03-17 2010-09-23 Curna, Inc. Traitement des maladies associées à l'homologue du delta-like 1 (dlk1) par inhibition du transcrit antisens naturel de dlk1
WO2010114770A1 (fr) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Conjugués polymère-agent, particules, compositions et procédés d'utilisation apparentés
WO2010114768A1 (fr) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Conjugués polymère-épothilone, particules, compositions et procédés d'utilisation apparentés
JP2012522055A (ja) * 2009-03-30 2012-09-20 セルリアン・ファーマ・インコーポレイテッド ポリマー‐薬剤抱合体、粒子、組成物、および関連する使用方法
US9145555B2 (en) 2009-04-02 2015-09-29 California Institute Of Technology Integrated—ligand-responsive microRNAs
EP3524275A1 (fr) 2009-04-22 2019-08-14 Massachusetts Institute Of Technology Suppression immunitaire innée permettant la distribution répétée de longues molécules d'arn
WO2010127195A2 (fr) 2009-05-01 2010-11-04 Curna, Inc. Oligonucléotides antisens d'hémoglobines
US9155754B2 (en) 2009-05-06 2015-10-13 Curna, Inc. Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1
JP6250930B2 (ja) 2009-05-06 2017-12-20 クルナ・インコーポレーテッド トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療
US8957037B2 (en) 2009-05-18 2015-02-17 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
KR101703695B1 (ko) 2009-05-22 2017-02-08 큐알엔에이, 인크. 전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의해 ｔｆｅ3 및 인슐린 수용체 기질 2(ｉｒｓ2)의 치료
CA2764683A1 (fr) 2009-05-28 2010-12-02 Joseph Collard Traitement de maladies associees a un gene antiviral grace a l'inhibition d'un produit de transcription antisens naturel d'un gene antiviral
IT1398857B1 (it) 2009-06-10 2013-03-21 Univ Padova Coniugati polimerici fosfolipidi
KR101702689B1 (ko) 2009-06-16 2017-02-06 큐알엔에이, 인크. Ｐｏｎ1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(ｐｏｎ1) 관련된 질환의 치료
EP2443237B1 (fr) 2009-06-16 2017-02-22 CuRNA, Inc. Traitement de maladies liées au gène du collagène par inhibition d'un produit de transcription antisens naturel à un gène du collagène
EP2446036B1 (fr) 2009-06-24 2017-03-01 CuRNA, Inc. Traitement de maladies associées au récepteur de facteur nécrosant des tumeurs 2 (tnfr2) par inhibition de la transcription antisens naturelle de tnfr2
ES2583691T3 (es) 2009-06-26 2016-09-21 Curna, Inc. Tratamiento de enfermedades relacionadas con un gen del síndrome de Down mediante la inhibición de una transcripción antisentido natural a un gen del síndrome de Down
JP6128848B2 (ja) 2009-08-05 2017-05-17 クルナ・インコーポレーテッド インスリン遺伝子（ｉｎｓ）に対する天然アンチセンス転写物の抑制によるインスリン遺伝子（ｉｎｓ）関連疾患の治療
CA2771172C (fr) 2009-08-25 2021-11-30 Opko Curna, Llc Traitement de maladies associees a la proteine d'activation de gtpase contenant un motif iq (iqgap), par inhibition d'un transcrit antisens naturel de iqgap
EP2473522B1 (fr) 2009-09-02 2016-08-17 Genentech, Inc. Mutant smoothened et ses méthodes d'utilisation
EP4089169A1 (fr) 2009-10-12 2022-11-16 Larry J. Smith Procédés et compositions permettant de moduler l'expression génique à l'aide de médicaments à base d'oligonucléotides administrés in vivo ou in vitro
RU2539772C2 (ru) 2009-10-22 2015-01-27 Дженентек, Инк. Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
WO2011056234A1 (fr) 2009-11-06 2011-05-12 Fibrogen, Inc. Traitement de troubles induits par un rayonnement
EP2507264A2 (fr) 2009-11-30 2012-10-10 F. Hoffmann-La Roche AG Anticorps pour le traitement et de diagnostic des tumeurs exprimant slc34a2 (tat211 = seqid 2)
CA2783934A1 (fr) 2009-12-11 2011-06-16 Genecode As Procedes destines a faciliter la survie de cellules neuronales en utilisant des mimetiques de ligands de la famille des gdnf (gfl) ou des activateurs de la voie de signalisation du ret
DK2513310T3 (en) 2009-12-16 2018-02-05 Curna Inc TREATMENT OF DISEASES CONNECTED WITH MEMBRANE-BONDED TRANSCRIPTION FACTOR Peptidase, site 1 (MBTPS1), BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MBTPS1
CN102781480B (zh) 2009-12-23 2018-07-27 库尔纳公司 通过抑制解偶联蛋白2(ucp2)的天然反义转录物而治疗ucp2相关疾病
NO2516648T3 (fr) 2009-12-23 2018-04-07
RU2611186C2 (ru) 2009-12-29 2017-02-21 Курна, Инк. ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С ОПУХОЛЕВЫМ БЕЛКОМ 63 (р63), ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К р63
ES2657452T3 (es) 2009-12-29 2018-03-05 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor respiratorio nuclear 1 (NRF1) mediante inhibición de transcrito antisentido natural a NRF1
EP2521784B1 (fr) 2010-01-04 2017-12-06 CuRNA, Inc. Traitement de maladies liées au facteur de régulation de l'interféron 8 (irf8) par l'inhibition du produit de transcription antisens naturel de l'irf8
CN102822342B (zh) 2010-01-06 2017-05-10 库尔纳公司 通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
DK2524039T3 (en) 2010-01-11 2018-03-12 Curna Inc TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
EP2525808A2 (fr) 2010-01-19 2012-11-28 The Trustees Of Columbia University In The City Of New York Emploi de l'ostéocalcine dans le traitement de troubles de la reproduction chez le mâle
RU2611192C2 (ru) 2010-01-25 2017-02-21 Курна, Инк. ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С РНКазой Н1, ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К РНКазе Н1
EP2539452B1 (fr) 2010-02-22 2016-07-27 CuRNA, Inc. Traitement de maladies liées à la pyrroline-5-carboxylate réductase 1 (pycr1) par inhibition du produit de transcription antisens naturel de pycr1
CA2787657A1 (fr) 2010-02-23 2011-09-01 Genentech, Inc. Compositions et methodes pour le diagnostic et le traitement d'une tumeur
WO2011119852A1 (fr) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Composés d'arni de taille réduite s'auto-administrant
JP5978203B2 (ja) 2010-04-09 2016-08-24 カッパーアールエヌエー，インコーポレイテッド Ｆｇｆ２１に対する天然アンチセンス転写物の阻害による線維芽細胞増殖因子（ｆｇｆ２１）線維芽細胞増殖因子ｆｇｆ２１）関連疾患の治療
ES2625689T3 (es) 2010-04-29 2017-07-20 Ionis Pharmaceuticals, Inc. Modulación de la expresión de transtiretina
US9089588B2 (en) 2010-05-03 2015-07-28 Curna, Inc. Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2011143511A2 (fr) 2010-05-12 2011-11-17 Columbia University Procédés de production de cellules entéroendocrines capables de fabriquer et de sécréter de l'insuline
TWI586356B (zh) 2010-05-14 2017-06-11 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
ES2664572T3 (es) 2010-05-26 2018-04-20 Curna, Inc. Tratamiento de enfermedades relacionadas con el homólogo atonal 1 (ATOH1) mediante inhibición del transcrito antisentido natural a ATOH1
EP2588490B1 (fr) 2010-07-02 2017-02-22 Angiochem Inc. Polypeptides courts contenant des acides aminés d pour conjugués thérapeutiques et leurs utilisations
ES2663598T3 (es) 2010-07-14 2018-04-16 Curna, Inc. Tratamiento de enfermedades relacionadas con el homólogo de discos grandes (dlg) mediante la inhibición del transcrito antisentido natural a dlg
DK2625197T3 (en) 2010-10-05 2016-10-03 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
JP5986998B2 (ja) 2010-10-06 2016-09-06 カッパーアールエヌエー，インコーポレイテッド シアリダーゼ４（ｎｅｕ４）への天然アンチセンス転写物の阻害によるｎｅｕ４関連疾患の治療
WO2012054723A2 (fr) 2010-10-22 2012-04-26 Opko Curna Llc Traitement de maladies associées à l'alpha-l-iduronidase (idua) par inhibition du transcrit antisens endogène de idua
JP6073795B2 (ja) 2010-10-27 2017-02-01 カッパーアールエヌエー，インコーポレイテッド インターフェロン関連発生制御因子１（ｉｆｒｄ１）への天然アンチセンス転写物の阻害によるｉｆｒｄ１関連疾患の治療
US20140134181A1 (en) 2010-11-05 2014-05-15 Kenneth E. Lipson Treatment Method For Lung Remodeling Diseases
CA2818824A1 (fr) 2010-11-23 2012-05-31 Joseph Collard Traitement de maladies associees a nanog par l'inhibition d'un transcript antisens naturel de nanog
CA2825059A1 (fr) 2011-02-02 2012-08-09 Excaliard Pharmaceuticals, Inc. Procede de traitement de cheloides ou de cicatrices hypertrophiees a l'aide de composes antisens ciblant un facteur de croissance de tissu conjonctif (ctgf)
WO2012109495A1 (fr) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cibles cellulaires de thiazolidinediones
WO2012142458A1 (fr) 2011-04-13 2012-10-18 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression du gène ptp1b
EP2718439B1 (fr) 2011-06-09 2017-08-09 CuRNA, Inc. Traitement des maladies associées à la frataxine (fxn) par inhibition de la transcription de l'anti-sens naturel de la fxn
CN103597074A (zh) 2011-06-16 2014-02-19 Isis制药公司 成纤维细胞生长因子受体4表达的反义调节
BR112014006587B1 (pt) 2011-09-20 2021-07-27 Ionis Pharmaceuticals, Inc Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
WO2013063313A1 (fr) 2011-10-25 2013-05-02 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression de gccr
US20150004219A1 (en) * 2012-02-02 2015-01-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Stable liposomes for drug delivery
CN104583405A (zh) 2012-03-15 2015-04-29 科纳公司 通过抑制脑源神经营养因子(bdnf)的天然反义转录物治疗bdnf相关疾病
JP2015524410A (ja) * 2012-07-18 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． エポキシケトン系プロテアソーム阻害剤のリポソーム組成物
EP2943194A1 (fr) 2012-09-17 2015-11-18 Chemedest Ltd. Traitement d'une neuropathie périphérique à l'aide d'agonistes du récepteur de type 3 de gfr(alpha)3
JP6469012B2 (ja) 2012-10-22 2019-02-13 ファウンテン バイオファーマ インコーポレーテッドＦｏｕｎｔａｉｎ Ｂｉｏｐｈａｒｍａ Ｉｎｃ． インターロイキン−６に対する抗体およびその使用
CA2894846A1 (fr) 2012-12-12 2014-06-19 Temple University - Of The Commonwealth System Of Higher Education Compositions et methodes de traitement du cancer
WO2014152497A2 (fr) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Ostéocalcine en tant que traitement de troubles cognitifs
ES2862125T3 (es) 2013-06-13 2021-10-07 Antisense Therapeutics Ltd Terapia combinada para acromegalia
US20150197534A1 (en) 2013-09-05 2015-07-16 Sarepta Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
US10036020B2 (en) 2013-09-19 2018-07-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for inhibiting JC virus (JCV)
US9987375B2 (en) * 2013-09-23 2018-06-05 Amirhossein Sahebkar Method and composition for treatment of dyslipidemia and other diseases
US10934550B2 (en) 2013-12-02 2021-03-02 Phio Pharmaceuticals Corp. Immunotherapy of cancer
WO2015116902A1 (fr) 2014-01-31 2015-08-06 Genentech, Inc. Récepteurs couplés aux protéines g dans la signalisation hedgehog
CA2937539A1 (fr) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened et methodes d'utilisation de celui-ci
WO2015171918A2 (fr) 2014-05-07 2015-11-12 Louisiana State University And Agricultural And Mechanical College Compositions et leurs utilisations thérapeutiques
US10487314B2 (en) 2014-06-26 2019-11-26 The Trustees Of Columbia University In The City Of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
WO2016033424A1 (fr) 2014-08-29 2016-03-03 Genzyme Corporation Méthodes de prévention et de traitement d'évènements indésirables cardiovasculaires majeurs à l'aide de composés modulant l'apolipoprotéine b
US11191811B2 (en) 2014-11-19 2021-12-07 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for frailty associated with aging
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
MA50829A (fr) 2015-06-01 2018-04-11 Sarepta Therapeutics Inc Exclusion d'exon induite pat technologie antisens dans le collagène de type vii
WO2017004518A1 (fr) * 2015-07-02 2017-01-05 The Regents Of The University Of California Formulations thérapeutiques nanoliposomales à base de nitroglycérine à ciblage de site
WO2017058881A1 (fr) 2015-09-28 2017-04-06 The Trustees Of Columbia University In The City Of New York Utilisation de la pentoxifylline sous thérapies de blocage des points de contrôle immunitaires pour le traitement du mélanome
JP2018530560A (ja) 2015-10-09 2018-10-18 サレプタ セラピューティクス， インコーポレイテッド デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
AU2016349954B2 (en) 2015-11-05 2022-08-25 Antisense Therapeutics Ltd Mobilizing leukemia cells
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
AU2016377398B2 (en) 2015-12-23 2022-10-13 Repluca Pty Ltd Nucleic acid oligomers and uses therefor
JP2019509721A (ja) 2016-02-04 2019-04-11 キュリス，インコーポレイテッド 突然変異体スムースンド及びその使用方法
CA3021267A1 (fr) 2016-04-18 2017-10-26 Sarepta Therapeutics, Inc. Oligomeres antisens et procedes d'utilisation de ceux-ci pour le traitement de maladies associees au gene de l'alpha-glucosidase acide
US11123433B2 (en) * 2016-06-01 2021-09-21 Board Of Supervisors Of Louisiana State University Hydrophobically modified polypeptoids and uses thereof
WO2018209288A1 (fr) 2017-05-12 2018-11-15 Massachusetts Institute Of Technology Complexes d'arn double brin de protéine argonaute et leurs utilisations
WO2019055460A1 (fr) 2017-09-13 2019-03-21 The Children's Medical Center Corporation Compositions et méthodes pour le traitement de maladies associées aux transposons
JP7394753B2 (ja) 2017-10-18 2023-12-08 サレプタ セラピューティクス， インコーポレイテッド アンチセンスオリゴマー化合物
JP7522038B2 (ja) 2018-04-06 2024-07-24 ザ チルドレンズ メディカル センター コーポレーション 体細胞リプログラミングおよびインプリンティングのモジュレートのための組成物および方法
AU2022261124A1 (en) 2021-04-22 2023-10-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
WO2023245293A1 (fr) * 2022-06-23 2023-12-28 Oligo Medic Inc. Architecture de nanoparticules pour furtivité in vivo et ciblage sélectif combinés

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986004145A1 (fr) * 1984-12-31 1986-07-17 University Of New Mexico Modification de proteines avec peg
DE3935257A1 (de) * 1989-10-23 1991-04-25 Langhals Heinz Mit antikoerpern verknuepfte liposomen als traeger fuer einen gezielten transport von wirkstoffen und reagenzien - fluoreszenzmarkierung der transportwege und des wirkorts
WO1991005546A1 (fr) * 1989-10-20 1991-05-02 Liposome Technology, Inc. Procede et composition de traitement de tumeurs solides
EP0526700A2 (fr) * 1991-05-23 1993-02-10 Mitsubishi Chemical Corporation Liposome lié à une protéine et contenant un médicament

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885172A (en) * 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4898735A (en) * 1985-12-06 1990-02-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Liposome/doxorubicin composition and method
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US4948590A (en) * 1987-06-09 1990-08-14 Yale University Avidin or streptavidin conjugated liposomes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986004145A1 (fr) * 1984-12-31 1986-07-17 University Of New Mexico Modification de proteines avec peg
WO1991005546A1 (fr) * 1989-10-20 1991-05-02 Liposome Technology, Inc. Procede et composition de traitement de tumeurs solides
US5213804A (en) * 1989-10-20 1993-05-25 Liposome Technology, Inc. Solid tumor treatment method and composition
DE3935257A1 (de) * 1989-10-23 1991-04-25 Langhals Heinz Mit antikoerpern verknuepfte liposomen als traeger fuer einen gezielten transport von wirkstoffen und reagenzien - fluoreszenzmarkierung der transportwege und des wirkorts
EP0526700A2 (fr) * 1991-05-23 1993-02-10 Mitsubishi Chemical Corporation Liposome lié à une protéine et contenant un médicament

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A.L. KLIBANOV ET AL.: "long-circulating liposomes: development and perspectives", JOURNAL OF LIPOSOME RESEARCH, vol. 2, no. 3, 1992, NEW YORK (US), pages 321 - 334, XP000303896 *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463066A (en) * 1993-12-06 1995-10-31 Nof Corporation Phospholipid derivative and reactive vesicle-forming agent
US5540935A (en) * 1993-12-06 1996-07-30 Nof Corporation Reactive vesicle and functional substance-fixed vesicle
EP0657463A1 (fr) * 1993-12-06 1995-06-14 Nof Corporation Dérivés de phospholipides et vésicule les contenant
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US7507407B2 (en) 1994-11-09 2009-03-24 The Regents Of The University Of California Immunoliposomes that optimize internationalization into target cells
WO1996034598A1 (fr) * 1995-05-03 1996-11-07 Polymasc Pharmaceuticals Plc Inclusion dans des tissus
US6673364B1 (en) 1995-06-07 2004-01-06 The University Of British Columbia Liposome having an exchangeable component
EP1655039A3 (fr) * 1996-04-18 2010-01-27 The Regents Of The University Of California Immunoliposomes optimisant l' internalisation dans des cellules cibles
EP0912198A4 (fr) * 1996-04-18 2000-04-12 Univ California Immunoliposomes optimisant l'internalisation dans des cellules cibles
WO1998008489A1 (fr) * 1996-08-26 1998-03-05 Transgene S.A. Complexes acides nucleiques/lipides cationiques
US6271208B1 (en) 1996-08-26 2001-08-07 Transgene S.A. Process of making cationic lipid-nucleic acid complexes
EP0903152A3 (fr) * 1997-09-17 1999-07-07 Mitsubishi Chemical Corporation Dérivés polymeriques aquasolubles et complexes les contenant
EP1352662A1 (fr) * 1997-09-17 2003-10-15 Mitsubishi Chemical Corporation Conjugués d'un anticorps avec un polymère hydrosoluble, utilisés pour des immunoliposomes
US6734171B1 (en) 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
EP2015066A1 (fr) * 1997-11-03 2009-01-14 Roche Diagnostics GmbH Biomolécules dérivés du polyéthylèneglycole et leur utilisation dans des procédés de détection hétérogènes
WO1999033493A1 (fr) * 1997-12-23 1999-07-08 Inex Pharmaceuticals Corporation Oligomeres polyamidiques
US6586559B2 (en) 1997-12-23 2003-07-01 Inex Pharmaceuticals Corporation Polyamide oligomers
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
EP1170018A4 (fr) * 1999-03-17 2002-04-17 Mitsubishi Chem Corp Complexe lie par un ligand
WO2001011069A1 (fr) 1999-08-06 2001-02-15 Celltech R&D Limited Complexes de lipide congeles/decongeles et leur preparation
KR100822566B1 (ko) * 2000-02-21 2008-04-16 안티-캔서 세라퓨틱 인벤션즈 에이에스 방사성 치료 리포좀
JP2003522808A (ja) * 2000-02-21 2003-07-29 アンチキャンサー セラピューティック インベンションズ エイエス 放射線治療用リポソーム
WO2001060417A3 (fr) * 2000-02-21 2002-02-07 Anticancer Therapeutic Inv Sa Liposomes therapeutiques radioactifs
WO2005049091A3 (fr) * 2003-11-13 2006-11-09 Elan Pharma Int Ltd Compositions comprenant des anticorps et procedes d'utilisation de celles-ci pour l'administration ciblee d'un agent actif nanoparticulaire
JP2007511513A (ja) * 2003-11-13 2007-05-10 エラン ファーマ インターナショナル リミテッド 抗体を含む組成物および標的化されたナノ粒子活性物質送達のためのその使用法
WO2012117385A2 (fr) 2011-03-03 2012-09-07 WROCŁAWSKIE CENTRUM BADAŃ EIT+ Sp z o.o. Formulation liposomale comprenant une substance active antitumorale, procédé de préparation et compositions pharmaceutiques la comprenant
US20220125728A1 (en) * 2020-10-22 2022-04-28 Rutgers, The State University Of New Jersey Strategies to Enhance Lung Cancer Treatment
US11896713B2 (en) * 2020-10-22 2024-02-13 Rutgers, The State University Of New Jersey Strategies to enhance lung cancer treatment

Also Published As

Publication number Publication date
AU6527294A (en) 1994-10-24
US5527528A (en) 1996-06-18

Similar Documents

Publication Publication Date Title
US5527528A (en) Solid-tumor treatment method
US5620689A (en) Liposomes for treatment of B-cell and T-cell disorders
CA2157410C (fr) Composition modulatrice et methode ameliorees pour faciliter la circulation
CA2067178C (fr) Methode et composition pour le traitement des tumeurs solides
US6043094A (en) Therapeutic liposome composition and method
US7150882B2 (en) Enhanced circulation effector composition and method
US5820873A (en) Polyethylene glycol modified ceramide lipids and liposome uses thereof
HK1047550A1 (en) Fusion liposome synthesizing agent and method of use
CA2388026A1 (fr) Apport cible de medicament au moyen d'un ligand des recepteurs de cd44
JPH04346918A (ja) 薬剤含有タンパク質結合リポソーム
JP3671054B2 (ja) 医薬組成物
Zalipsky Polyethylene glycol-lipid conjugates
Emanuel et al. Preparation and characterization of doxorubicin-loaded sterically stabilized immunoliposomes
Singh et al. Targeting of methotrexate-containing liposomes with a monoclonal antibody against human renal cancer
JP2006519262A (ja) リポソームにより誘導される補体活性化の減少のためのリポソーム組成物
EP0179444B1 (fr) Utilisation d'une composition de particules micellaires encapsulant un agent chimiothérapeutique pour le ciblage intraveineux des tumeurs(17.05.90)
JP3759759B2 (ja) リポソームおよび薬物運搬体
WO1994021281A1 (fr) Composition polymere-polypeptide et procede d'administration de ladite composition
JP4385152B2 (ja) ２価反応性水溶性高分子誘導体及びそれを含有する複合体
KR102708349B1 (ko) 씨 알지디 에이씨피 케이로 변형된 장시간 순환 리포솜
Hirota et al. Targeting cancer therapy in mice by use of newly developed immunoliposomes bearing adriamycin
AU736055B2 (en) Fusogenic liposome composition and method
JPH0390037A (ja) リポソーム製剤
Agrawal et al. Pharmacology and Toxicology: Basic and Clinical Aspects

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA